Is Johnson & Johnson cheap at 38 times earnings?

A beat, a raise, a $5.5 billion settlement - and a 5.7% drop

Johnson & Johnson ($JNJ) delivered the quarter to 27 September 2026 with sales of $25.40 billion, up 5.9%, and adjusted EPS of $2.59 against the $2.52 analysts expected. It raised 2026 guidance for the third time, to $101.2 billion of sales and $11.10 of adjusted EPS at the midpoint. The next day the stock fell 5.7% - the worst reaction to any of its last five earnings reports.

The headline culprit is the reported EPS of $0.09, down from $2.12 in the quarter to September 2025, after the talc resolution, the Firefly Bio charge and the Sail deal costs. The gap between $6.34 billion of adjusted net earnings and $210 million of reported earnings is roughly $6.1 billion. But the $5.5 billion talc number had been public since 27 July 2026, and markets rarely sell a charge they have known about for 11 weeks.

What the market actually repriced is 2027. MedTech grew only 2.5% to $8.64 billion, short of the $8.71 billion expected for the second quarter in a row, with Middle East disruption to orders cited. Stelara biosimilars took about 690 basis points off Innovative Medicine growth. Adjusted pretax margin fell from 35.2% to 30.2% of sales. And management repeated that Firefly and Sail will cut 2027 adjusted EPS by about $1.36 - 12% of what 2026 is guided to earn.

38x earnings on the screen, 23x on guidance

The trailing P/E of 37.9x looks like an overheated stock next to the 21.9x industry median. It is largely an accounting artefact: the trailing figure carries a quarter in which the company earned $0.09 per share. On the $11.10 guidance the price is 23.0x - the kind of multiple the market pays for a steady drug maker, not a bubble. The P/E ratio page explains why one distorted quarter can double a trailing multiple.

The real expansion sits elsewhere. EV/EBITDA has gone from 13.0x at 28 December 2025 to 20.7x; price-to-sales from 5.4x to 6.1x; price to free cash flow from 25.6x to 32.6x. The free cash flow yield - cash generated per dollar of market value - is 3.06% against 4.41% for the industry. That is what a 32.3% one-year gain against 14.9% for the S&P 500 does to a stock whose profit is guided to grow 2.9%.

Fair value $261.14: why the model stops 2.2% above the price

The FPI fair value is $261.14, which puts the $255.57 price 2.2% below it - fairly valued. The DCF leg, half the weight, runs on the $21 billion free cash flow guided for 2026 (3.4% of the $610.67 billion market cap), net debt of about $28 billion, a 16.2% net margin and 14.7% return on invested capital. Both beat the industry (13.6% and 10.1%), and that quality is what keeps the number above the price at all.

The relative leg, 30% of the weight, pulls the number down. At 20.7x EV/EBITDA, the stock trades 41% above the 14.7x industry median and above Amgen at 16.8x, a peer with 11.8% three-year revenue growth against 5.6% here. The analyst leg, 20%, pulls it up with a $284.50 mean target. The blend lands at $261.14 - between the 200-day average of $244.12 and the 50-day average of $265.23. In plain terms: a high-quality business priced as a high-quality business, with no discount left.

Street vs model: $284.50 against $261 - a 9% gap built on 2027

Wall Street counts 21 buy, 16 hold and 3 sell ratings. Targets run from a low of $260 - almost exactly the FPI number - through a median of $280 to a high of $320; the mean of $284.50 sits 8.9% above the model and 11.3% above the price. Post-earnings moves were small and mostly down: on 14 October 2026 RBC Capital cut from $290 to $280 and Wells Fargo from $282 to $275, UBS set $270, Leerink $272, Bernstein $270 on 15 October; Wells Fargo then moved back up to $287 on 16 October. Targets issued in the last month average $277.75 against $286.50 for the last quarter - a 3.1% drift lower.

The gap has one explanation. The Street models a 2027 EPS rebound that absorbs the $1.36 dilution and credits the DePuy Synthes orthopaedics spin-off targeted for mid-2027; the model weighs cash flow already visible and the multiples peers trade at today. Insiders are closer to the model than to the Street: $142.3 million of sales in 12 months against one purchase of $257,688. The CEO sold 123,291 shares for $32.2 million at $261-262 on 13 August 2026 - within a dollar of the fair value.

Three numbers to watch before 8 December

The up scenario needs 2027 guidance at the Enterprise Business Review on 8 December 2026 that swallows the $1.36 hit and still shows adjusted EPS above $11.10, MedTech back above 4% operational growth, and the talc deal clearing its 95% claimant participation threshold so the first payment of no more than $3 billion in 2027 becomes the final word on a 15-year liability. That is the path to the $280 median target, 9.6% above the price.

The down scenario is another MedTech quarter under 3% on 20 January 2027 (consensus: EPS $2.93, revenue $26.45 billion), 2027 EPS guidance under $11, or a close below the 200-day average at $244.12, 4.5% under the current price. Three signals to track:

• Full-year 2026 free cash flow at $21 billion - the figure the DCF is built on.
• $261.14 - the fair value that separates fair from expensive at today's cash flows.
• The $1.34 quarterly dividend, raised 3.1% on 14 April 2026 for the 64th consecutive year, which yields 2.08% and costs about $13 billion a year against $21 billion of free cash flow - the floor argument if 2027 disappoints.